The rapidly changing global pharmaceutical landscape reached another milestone yesterday, as Takeda Pharmaceutical Co completed its US$62 billion acquisition of Shire PLC.
Takeda’s purchase was the world’s biggest announced acquisition of last year, transforming the 237-year-old Japanese company into a top 10 drugmaker with lucrative therapies for rare diseases and a sizable footprint in the US.
It is part of a larger shift in the industry as drugmakers scramble to consolidate, seeking to bulk up to survive increasing pressure from stricter regulations on drug prices and looming patent expirations.
Already this year, the Takeda deal has been trumped in size by Bristol-Myers Squibb Co’s US$74 billion agreement last week to buy Celgene Corp.
Here is how the supersized Takeda is to look in the increasingly evolving pharmaceutical landscape:
Takeda and Shire’s combined revenue catapult it into the ranks of the global pharmaceutical majors — the first Japanese company to reach the top 10.
The new Takeda would have ranked No. 9 among the biggest drugmakers by revenue, but Bristol-Myers’ deal with Celgene, if it succeeds, would push it down one notch.
The company would also hold a unique position in being a big pharmaceutical company with a focus on rare diseases acquired from Shire’s portfolio.
One of the key drivers for the acquisition was to gain further exposure to the US, the world’s most profitable drug market. Japan has not become a dependable source for growth because of a shrinking population and regulatory pressure that has pushed down drug prices nearly every year.
Although the US also poses a drug-pricing risk, it is one most pharma giants are willing to take for the revenue stream.
Takeda would contribute further to the dealmaking frenzy, thanks to the heavy debt load it has taken on.
The company has laid out a scenario of a potential US$10 billion in divestments in an effort to deleverage. Investors should expect asset sales this year, chief executive officer Christophe Weber said on Monday.
The company is looking to divest non-core businesses outside Japan where the company is not an industry leader and does not have critical mass in the market.
Takeda’s debt load was the issue that drew the biggest fire from critics of the deal, and caused S&P Global Ratings to downgrade the drugmaker yesterday, saying that the company is unlikely to recover quickly from worsening financial ratios. Moody’s Investors Service lowered its rating last month.
Net borrowings would more than double to nearly five times earnings after it takes on about US$30 billion in debt to acquire Shire, plus the debt on that company’s books. That is compared with an industry average multiple of about one.
The company has said it intends to deleverage to a debt ratio multiple of about two within five years.
The Eurovision Song Contest has seen a surge in punter interest at the bookmakers, becoming a major betting event, experts said ahead of last night’s giant glamfest in Basel. “Eurovision has quietly become one of the biggest betting events of the year,” said Tomi Huttunen, senior manager of the Online Computer Finland (OCS) betting and casino platform. Betting sites have long been used to gauge which way voters might be leaning ahead of the world’s biggest televised live music event. However, bookmakers highlight a huge increase in engagement in recent years — and this year in particular. “We’ve already passed 2023’s total activity and
Nvidia Corp CEO Jensen Huang (黃仁勳) today announced that his company has selected "Beitou Shilin" in Taipei for its new Taiwan office, called Nvidia Constellation, putting an end to months of speculation. Industry sources have said that the tech giant has been eyeing the Beitou Shilin Science Park as the site of its new overseas headquarters, and speculated that the new headquarters would be built on two plots of land designated as "T17" and "T18," which span 3.89 hectares in the park. "I think it's time for us to reveal one of the largest products we've ever built," Huang said near the
BIG BUCKS: Chairman Wei is expected to receive NT$34.12 million on a proposed NT$5 cash dividend plan, while the National Development Fund would get NT$8.27 billion Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, yesterday announced that its board of directors approved US$15.25 billion in capital appropriations for long-term expansion to meet growing demand. The funds are to be used for installing advanced technology and packaging capacity, expanding mature and specialty technology, and constructing fabs with facility systems, TSMC said in a statement. The board also approved a proposal to distribute a NT$5 cash dividend per share, based on first-quarter earnings per share of NT$13.94, it said. That surpasses the NT$4.50 dividend for the fourth quarter of last year. TSMC has said that while it is eager
China yesterday announced anti-dumping duties as high as 74.9 percent on imports of polyoxymethylene (POM) copolymers, a type of engineering plastic, from Taiwan, the US, the EU and Japan. The Chinese Ministry of Commerce’s findings conclude a probe launched in May last year, shortly after the US sharply increased tariffs on Chinese electric vehicles, computer chips and other imports. POM copolymers can partially replace metals such as copper and zinc, and have various applications, including in auto parts, electronics and medical equipment, the Chinese ministry has said. In January, it said initial investigations had determined that dumping was taking place, and implemented preliminary
RSS